Journal
EUROPEAN RESPIRATORY JOURNAL
Volume 38, Issue 2, Pages 277-284Publisher
EUROPEAN RESPIRATORY SOC JOURNALS LTD
DOI: 10.1183/09031936.00110510
Keywords
Biomarker; chronic obstructive pulmonary disease; induced sputum; screening; smoking; surfactant protein A
Categories
Funding
- Research Program for the Intelligent Monitoring Health and Well-being
- Finnish Antituberculosis Association Foundation
- Helsinki University Central Hospital (HUCH-EVO)
- Lapland Central Hospital
- Ida Montin Foundation
- Yrjo Jahnsson Foundation
Ask authors/readers for more resources
Serum surfactant protein (SP)-A has been postulated to associate with pulmonary fibrosis, but its role in cigarette smoking-related lung diseases is undefined. SP-A levels in plasma and induced sputum in nonsmokers, smokers with respiratory symptoms (cough and/or phlegm) and symptom-free smokers were assessed using a validated EIA method. A total of 474 current smokers without any diseases or medications were enrolled and followed for 2 yrs with 111 of them succeeding in stopping. Plasma SP-A level was detectable in all subjects and elevated in smokers independently of the symptoms compared to nonsmokers (p=0.001). After 2 yrs of follow-up, the SP-A level was higher in those who continued smoking compared to the quitters (p < 0.001). Plasma SP-A levels were associated with age, smoking history and lung function. Sputum (n=109) SP-A was nondetectable in most nonsmokers, whereas smoking and symptoms increased sputum SP-A highly significantly (p=0.001). In conclusion, SP-A may be involved in pathogenesis of cigarette smoking-related lung diseases. Further studies are needed to elucidate the role of SP-A in chronic obstructive pulmonary disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available